This relationship manifests in more aggressive tumor characteristics, including larger tumor size, increased lymph vascular invasion, and higher rates of metastasis, with high FOXM1 expression correlating with poorer clinical outcomes and increased recurrence rates in HER2-positive breast cancers [46]. Here, ERBB2 is linked to breast cancer.